HIV Vaccine Trial IAVI G001: Rare Antibody Precursors Triggered

Facebook ↗WhatsApp ↗

Originally published 2021-04-07.

An Experimental HIV Vaccine's Early Immune-Response Results

In early 2021, researchers from the International AIDS Vaccine Initiative (IAVI) and Scripps Research reported that an experimental HIV vaccine had done something no earlier candidate had managed in people: it switched on the rare immune cells that could, in principle, go on to make broadly neutralising antibodies against HIV. In the phase I trial, called IAVI G001, 97% of volunteers who received the vaccine showed this targeted response. It was an important first step, not a working vaccine, and it does not yet protect anyone from infection.

Below is a plain-language guide to what the trial tested, what "97%" actually means, why an HIV vaccine has been so hard to make, and how people can protect themselves while research continues.

What the IAVI G001 trial found

The trial enrolled 48 healthy adults at George Washington University in Washington, DC, and the Fred Hutchinson Cancer Center in Seattle. Volunteers received either a placebo or two doses of a lab-designed protein called eOD-GT8 60mer, given two months apart with an adjuvant made by GSK to boost the immune response.

The first results were presented at the HIV Research for Prevention conference in February 2021, and the full data were published in the journal Science on 2 December 2022. The vaccine was found to be safe, and in 97% of those who received it, it activated the specific family of B cells the team was aiming for. On average, each person started with about 30 to 65 of these precursor cells, which then multiplied and became better at binding their target after each dose.

William Schief, an immunologist at Scripps Research and IAVI who co-led the work, described it as a proof of concept: "This study demonstrates proof of principle for a new vaccine concept for HIV." He also noted how scarce the target was, saying the cells were "only about one in a million of all naïve B cells."

Germline targeting and broadly neutralising antibodies

Most vaccines teach the immune system to recognise a germ by showing it a harmless version or a piece of it. HIV defeats that approach because it mutates so quickly. Antibodies that block one strain often miss the next.

A small number of people living with HIV, however, eventually produce broadly neutralising antibodies, or bnAbs. These attack parts of the virus that hardly change, such as the site HIV uses to latch onto human CD4 cells, and can neutralise many different strains at once. The problem is that bnAbs normally take years to develop inside an infected person, and they come from very rare starting cells.

The strategy tested in G001 is called germline targeting. Instead of trying to produce finished bnAbs in one go, scientists design a sequence of vaccines. The first shot "primes" the rare precursor B cells. Later shots, using different designed proteins, are meant to guide those cells step by step until they mature into cells that secrete bnAbs. G001 tested only that first step, and it worked better than many experts expected.

Why an HIV vaccine has taken so long

Researchers have been chasing an HIV vaccine since the virus was identified in the early 1980s. In 1984 a US official even predicted one within two years. More than four decades later, none has been licensed.

Several features make HIV unusually difficult. It mutates rapidly and exists as many genetically different subtypes around the world. The vulnerable spots on its outer envelope are hidden behind a dense shield of sugar molecules. The virus also inserts itself into the DNA of the cells it infects and can hide there for years. And because almost nobody clears HIV naturally, there is no simple model of protective immunity to copy.

The trial record shows how hard it is. The RV144 study in Thailand, reported in 2009, cut infections by about 30%, too little to licence. Larger efficacy trials since then, including HVTN 702 (Uhambo) in South Africa, which stopped vaccinations in 2020, Imbokodo in southern Africa and Mosaico, which ended in 2023, failed to show meaningful protection.

What came after G001

Building on the result, IAVI and Scripps teamed up with Moderna to deliver the same priming antigen using mRNA technology, the platform used in some COVID-19 vaccines. Follow-up phase I trials included IAVI G002 at four US sites, which also tested a booster designed in the Schief lab, and IAVI G003 in Kigali, Rwanda, and Tembisa, South Africa, an important step because most new HIV infections occur in Africa. A separate trial, HVTN 302, tested mRNA versions of stabilised HIV envelope proteins as possible later boosters.

These are still early-stage studies focused on safety and immune responses. A complete germline-targeting vaccine would probably need several different shots, and proving that it actually prevents infection would require large efficacy trials lasting years. Funding is also a factor: in 2025 some US-funded HIV vaccine research was delayed by budget cuts.

HIV today: the numbers

According to UNAIDS, about 39.9 million people were living with HIV in 2023. That year there were roughly 1.3 million new infections and about 630,000 deaths from AIDS-related illnesses. Since the epidemic began, an estimated 42.3 million people have died of AIDS-related causes. Some older reports gave lower figures, such as 33 million deaths, which reflect earlier estimates.

Without treatment, HIV gradually damages the immune system and usually progresses to AIDS, though a small number of people stay well for many years. Treatment has transformed the picture: about 30.7 million people were on antiretroviral therapy at the end of 2023.

Protection that already works

The lack of a vaccine does not mean people are without protection. Several proven tools exist:

  • Treatment as prevention. People living with HIV who take effective treatment and keep the virus at undetectable levels do not pass it on to sexual partners, a principle often summed up as U=U (undetectable equals untransmittable). With treatment, life expectancy can approach that of people without HIV.
  • PrEP. Pre-exposure prophylaxis, medication taken by HIV-negative people, can reduce the risk of getting HIV through sex by up to 99% when used as directed. Long-acting injectable options are now also available in some countries.
  • PEP. Post-exposure prophylaxis can prevent infection after a possible exposure if it is started as soon as possible and within 72 hours, then taken daily for 28 days. Earlier reports suggesting a 24-hour window were too strict; the CDC gives 72 hours, while stressing that sooner is better.
  • Testing and condoms. Regular testing and consistent condom use remain simple, effective measures.

Anyone who thinks they may have been exposed to HIV, or wants to know whether PrEP is right for them, should talk to a doctor or a sexual health clinic.

The 2021 result did not deliver a vaccine, but it showed that the immune system can be steered with precision toward a goal that once seemed out of reach. That is why many scientists still regard it as one of the most encouraging developments in the long search for an HIV vaccine.

Sources: IFLScience, 5 April 2021: New HIV vaccine approach shows great promise in first-in-human trial; EATG, 5 December 2022: Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach; Wikipedia: HIV vaccine development; UNAIDS: global HIV statistics fact sheet; CDC: About PEP; Wikipedia: Pre-exposure prophylaxis.

COMMENTS